Gemcabene Mitigates Cytokine Storm Severity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively preventing or treating cytokine storms, particularly those induced by viral infections such as COVID-19, which can lead to severe inflammatory responses and high morbidity and mortality.
Innovation Solution
Administration of gemcabene or its pharmaceutically acceptable salt, either alone or in combination with other therapeutic agents, to patients at risk or already experiencing cytokine storms, to mitigate the severity of the inflammatory response and prevent progression to respiratory failure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccination is implemented to control respiratory virus outbreaks, then immunity and prevention capability are improved, but difficulty in preparation, distribution and immunization increases
Solution Approach 1:
The patent applies preliminary action by administering gemcabene prophylactically to high-risk patients before they contract the virus or before vaccination. This approach prepares the body in advance to prevent cytokine storm, reducing the need for complex post-infection treatments and potentially simplifying overall pandemic response logistics.
Solution Approach 2:
Gemcabene acts as an intermediary substance that mediates between the immune system's protective response and the harmful cytokine storm. It modulates the immune response to maintain protection while preventing excessive inflammation, effectively bridging the gap between immunity and safety.
2Reliability
If cytokine storm treatment is delayed, then initial viral control may be maintained, but progression to respiratory failure and multiple-organ failure increases
Solution Approach 1:
The patent emphasizes early administration of gemcabene at the first sign of cytokine storm or in high-risk patients before severe deterioration occurs. This preliminary intervention prevents progression to respiratory failure while maintaining viral control, addressing the timing contradiction between early treatment and disease progression.
Solution Approach 2:
Gemcabene applies preliminary anti-action by counteracting the cytokine storm response before it can cause severe inflammatory damage. The drug preemptively blocks the harmful inflammatory pathway while allowing the immune system to control the virus, preventing the harmful effects before they fully manifest.
3Object-affected harmful factors
If high doses of anti-inflammatory agents are administered, then cytokine storm severity is reduced, but risk of secondary complications and immunosuppression increases
Solution Approach 1:
The patent utilizes parameter changes by administering gemcabene at optimized doses (e.g., 300-900 mg/day) that achieve effective cytokine storm suppression while maintaining safe levels. This dose optimization balances inflammatory control with minimal immunosuppression and reduced secondary complications.
Solution Approach 2:
Gemcabene serves as an intermediary anti-inflammatory agent that modulates rather than completely suppresses the immune response. It provides intermediate control of the cytokine storm, reducing inflammatory damage while maintaining sufficient immune function to avoid secondary complications from over-suppression.
Data Source
AI summary
The present disclosure provides methods of treating and/or preventing cytokine storms with gemcabene or a pharmaceutically acceeptable salt thereof. Also disclosed are methods of treating inflammation caused by viral infections.